PDCD1 and B-cell chronic lymphocytic leukemia: Overall, our findings emphasize PDCD1’s central role in ibrutinib resistance through immune checkpoint pathways and support the rationale for combining BTK inhibitors with immune checkpoint blockade therapies in resistant CLL cases.